Investigating the role of IGF2BP2 in a specific type of leukemia
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia
This study is looking at how a protein called IGF2BP2 affects a specific type of aggressive leukemia, aiming to find new ways to help patients by understanding how changes in RNA might help the leukemia grow and survive.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11023107 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of IGF2BP2, a protein involved in RNA modification, in MLL-rearranged acute myeloid leukemia (AML). The study aims to explore how changes in m6A modification of messenger RNAs contribute to the development and persistence of this aggressive leukemia subtype. By examining the molecular mechanisms behind MLLr AML and the behavior of leukemia stem cells, the research seeks to identify new therapeutic strategies that could improve treatment outcomes for patients. The approach includes analyzing gene expression and the effects of IGF2BP2 on leukemia cell survival and proliferation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MLL-rearranged acute myeloid leukemia, particularly those who have not responded well to current therapies.
Not a fit: Patients with other types of leukemia or those who do not have MLL rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for patients with MLL-rearranged acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in targeting RNA modifications in cancer, suggesting that this approach may hold potential for success.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Chen, Jianjun — Beckman Research Institute/city of Hope
- Study coordinator: Chen, Jianjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.